Chapman & Hall/CRC Biostatistics Series

Statistical Methods for Healthcare Performance Monitoring



Alex Bottle
Paul Aylin



Statistical Methods for Healthcare Performance Monitoring

Alex Bottle

Imperial College London, United Kingdom

Paul Aylin

Imperial College London, United Kingdom



CRC Press Taylor & Francis Group 6000 Broken Sound Parkway NW, Suite 300 Boca Raton, FL 33487-2742

© 2017 by Taylor & Francis Group, LLC CRC Press is an imprint of Taylor & Francis Group, an Informa business

No claim to original U.S. Government works

Printed on acid-free paper Version Date: 20160510

International Standard Book Number-13: 978-1-4822-4609-4 (Hardback)

This book contains information obtained from authentic and highly regarded sources. Reasonable efforts have been made to publish reliable data and information, but the author and publisher cannot assume responsibility for the validity of all materials or the consequences of their use. The authors and publishers have attempted to trace the copyright holders of all material reproduced in this publication and apologize to copyright holders if permission to publish in this form has not been obtained. If any copyright material has not been acknowledged please write and let us know so we may rectify in any future reprint.

Except as permitted under U.S. Copyright Law, no part of this book may be reprinted, reproduced, transmitted, or utilized in any form by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying, microfilming, and recording, or in any information storage or retrieval system, without written permission from the publishers.

For permission to photocopy or use material electronically from this work, please access www.copyright.com (http://www.copyright.com/) or contact the Copyright Clearance Center, Inc. (CCC), 222 Rosewood Drive, Danvers, MA 01923, 978-750-8400. CCC is a not-for-profit organization that provides licenses and registration for a variety of users. For organizations that have been granted a photocopy license by the CCC, a separate system of payment has been arranged.

Trademark Notice: Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation without intent to infringe.

Library of Congress Cataloging-in-Publication Data

Names: Bottle, Alex, author. | Aylin, Paul, author.

Title: Statistical methods for healthcare performance monitoring / Alex Bottle and Paul Aylin.

Description: Boca Raton : Taylor & Francis, 2017. | Series: Chapman &

Hall/CRC biostatistics series; 92 | "A CRC title, part of the Taylor & Francis imprint, a member of the Taylor & Francis Group, the academic division of T&F Informa plc." | Includes bibliographical references and

index.
Identifiers: LCCN 2016006496 | ISBN 9781482246094 (alk. paper)
Subjects: LCSH: Medical care--Evaluation. | Medical statistics. | Medical

care--Quality control. | Medical care--Safety measures. Classification: LCC RA399.A1 B68 2016 | DDC 362.1072/7--dc23

LC record available at https://lccn.loc.gov/2016006496

Visit the Taylor & Francis Web site at http://www.taylorandfrancis.com

and the CRC Press Web site at http://www.crcpress.com

Statistical Methods for Healthcare Performance Monitoring

Chapman & Hall/CRC Biostatistics Series

Editor-in-Chief

Shein-Chung Chow, Ph.D., Professor, Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina

Series Editors

Byron Jones, Biometrical Fellow, Statistical Methodology, Integrated Information Sciences, Novartis Pharma AG, Basel, Switzerland

Jen-pei Liu, Professor, Division of Biometry, Department of Agronomy,

National Taiwan University, Taipei, Taiwan

Karl E. Peace, Georgia Cancer Coalition, Distinguished Cancer Scholar, Senior Research Scientist and Professor of Biostatistics, Jiann-Ping Hsu College of Public Health, Georgia Southern University, Statesboro, Georgia

Bruce W. Turnbull, Professor, School of Operations Research and Industrial Engineering, Cornell University, Ithaca, New York

Published Titles

Adaptive Design Methods in Clinical Trials, Second Edition

Shein-Chung Chow and Mark Chang

Adaptive Designs for Sequential Treatment Allocation

Alessandro Baldi Antognini

and Alessandra Giovagnoli

Adaptive Design Theory and Implementation Using SAS and R, Second Edition

Mark Chang

Advanced Bayesian Methods for

Medical Test Accuracy

Lyle D. Broemeling

Applied Biclustering Methods for Big and High-Dimensional Data Using R

Adetayo Kasim, Ziv Shkedy, Sebastian Kaiser, Sepp Hochreiter,

and Willem Talloen

Applied Meta-Analysis with R
Ding-Geng (Din) Chen and Karl E. Peace

Basic Statistics and Pharmaceutical

Statistical Applications, Second Edition
James E. De Muth

Bayesian Adaptive Methods for Clinical Trials

Scott M. Berry, Bradley P. Carlin, J. Jack Lee, and Peter Muller Bayesian Analysis Made Simple:

An Excel GUI for WinBUGS

Phil Woodward

Bayesian Designs for Phase I–II
Clinical Trials

Ying Yuan, Hoang Q. Nguyen,

and Peter F. Thall

Bayesian Methods for Measures of Agreement

Lyle D. Broemeling

Bayesian Methods for Repeated Measures

Lyle D. Broemeling

Bayesian Methods in Epidemiology Lyle D. Broemeling

Bayesian Methods in Health Economics

Gianluca Baio

Bayesian Missing Data Problems: EM, Data Augmentation and Noniterative

Data Augmentation and Noniterative Computation

Ming T. Tan, Guo-Liang Tian, and Kai Wang Ng

Bayesian Modeling in Bioinformatics

Dipak K. Dey, Samiran Ghosh, and Bani K. Mallick

Benefit-Risk Assessment in Pharmaceutical Research and Development

Andreas Sashegyi, James Felli,

比为试读, 需要完整PDF请访 and Rebecca Noel ngbook. com

Published Titles

Benefit-Risk Assessment Methods in Medical Product Development: Bridging **Qualitative and Quantitative Assessments**

Qi Jiang and Weili He

Biosimilars: Design and Analysis of Follow-on Biologics

Shein-Chung Chow **Biostatistics: A Computing Approach**

Stewart J. Anderson

Cancer Clinical Trials: Current and Controversial Issues in Design and

Analysis

Stephen L. George, Xiaofei Wang, and Herbert Pang

Causal Analysis in Biomedicine and

Epidemiology: Based on Minimal

Sufficient Causation

Mikel Aickin

Clinical and Statistical Considerations in Personalized Medicine

Claudio Carini, Sandeep Menon, and Mark Chang

Clinical Trial Data Analysis using R

Ding-Geng (Din) Chen and Karl E. Peace

Clinical Trial Methodology

Karl E. Peace and Ding-Geng (Din) Chen Computational Methods in Biomedical

Research

Ravindra Khattree and Dayanand N. Naik

Computational Pharmacokinetics Anders Källén

Confidence Intervals for Proportions

and Related Measures of Effect Size Robert G. Newcombe

Controversial Statistical Issues in **Clinical Trials**

Data Analysis with Competing Risks

and Intermediate States Ronald B. Geskus

Shein-Chung Chow

Data and Safety Monitoring Committees in Clinical Trials

Jay Herson Design and Analysis of Animal Studies

in Pharmaceutical Development Shein-Chung Chow and Jen-pei Liu Design and Analysis of Bioavailability

and Bioequivalence Studies, Third Edition Shein-Chung Chow and Jen-pei Liu Design and Analysis of Bridging Studies Jen-pei Liu, Shein-Chung Chow,

and Chin-Fu Hsiao Design & Analysis of Clinical Trials for

Economic Evaluation & Reimbursement: An Applied Approach Using SAS & STATA

Iftekhar Khan

Design and Analysis of Clinical Trials for Predictive Medicine Shigeyuki Matsui, Marc Buyse,

and Richard Simon Design and Analysis of Clinical Trials with

Time-to-Event Endpoints Karl E. Peace

Design and Analysis of Non-Inferiority Trials

and Ivan S. F. Chan Difference Equations with Public Health Applications

Mark D. Rothmann, Brian L. Wiens,

Lemuel A. Moyé and Asha Seth Kapadia **DNA Methylation Microarrays: Experimental Design and Statistical**

Analysis Sun-Chong Wang and Arturas Petronis **DNA Microarrays and Related Genomics**

Techniques: Design, Analysis, and Interpretation of Experiments David B. Allison, Grier P. Page,

T. Mark Beasley, and Jode W. Edwards Dose Finding by the Continual

Reassessment Method Ying Kuen Cheung

Dynamical Biostatistical Models Daniel Commenges and

Hélène Jacqmin-Gadda **Elementary Bayesian Biostatistics**

Lemuel A. Moyé

Empirical Likelihood Method in Survival Analysis Mai Zhou

Exposure-Response Modeling: Methods and Practical Implementation Jixian Wang

Published Titles

Frailty Models in Survival Analysis

Andreas Wienke

Fundamental Concepts for New Clinical Trialists

Scott Evans and Naitee Ting

Generalized Linear Models: A Bayesian Perspective

Dipak K. Dey, Sujit K. Ghosh, and Bani K. Mallick

Handbook of Regression and Modeling: Applications for the Clinical and Pharmaceutical Industries

Daryl S. Paulson

Inference Principles for Biostatisticians

lan C. Marschner

Interval-Censored Time-to-Event Data: Methods and Applications

Ding-Geng (Din) Chen, Jianguo Sun, and Karl E. Peace

Introductory Adaptive Trial Designs:

A Practical Guide with R

Mark Chang

Joint Models for Longitudinal and Timeto-Event Data: With Applications in R

Dimitris Rizopoulos

Measures of Interobserver Agreement and Reliability, Second Edition

Mohamed M. Shoukri

Medical Biostatistics, Third Edition

A. Indrayan

Meta-Analysis in Medicine and Health Policy

Dalene Stangl and Donald A. Berry

Mixed Effects Models for the Population Approach: Models, Tasks, Methods and Tools

Marc Lavielle

Modeling to Inform Infectious Disease Control

Niels G. Becker

Modern Adaptive Randomized Clinical Trials: Statistical and Practical Aspects Oleksandr Sverdlov

Monte Carlo Simulation for the Pharmaceutical Industry: Concepts, Algorithms, and Case Studies Mark Chang

Multiregional Clinical Trials for Simultaneous Global New Drug Development

Joshua Chen and Hui Quan

Multiple Testing Problems in Pharmaceutical Statistics

Alex Dmitrienko, Ajit C. Tamhane, and Frank Bretz

Noninferiority Testing in Clinical Trials: Issues and Challenges

Tie-Hua Ng

Optimal Design for Nonlinear Response Models

Valerii V. Fedorov and Sergei L. Leonov

Patient-Reported Outcomes:

Measurement, Implementation and Interpretation

Joseph C. Cappelleri, Kelly H. Zou, Andrew G. Bushmakin, Jose Ma. J. Alvir, Demissie Alemayehu, and Tara Symonds

Quantitative Evaluation of Safety in Drug Development: Design, Analysis and

Reporting

Qi Jiang and H. Amy Xia

Quantitative Methods for Traditional Chinese Medicine Development

Shein-Chung Chow

Randomized Clinical Trials of Nonpharmacological Treatments Isabelle Boutron, Philippe Ravaud,

and David Moher

Randomized Phase II Cancer Clinical Trials

Sin-Ho Jung

Sample Size Calculations for Clustered and Longitudinal Outcomes in Clinical Research

Chul Ahn, Moonseong Heo, and Song Zhang

Published Titles

Sample Size Calculations in Clinical

Research, Second Edition

Shein-Chung Chow, Jun Shao, and Hansheng Wang

Statistical Analysis of Human Growth

and Development

Yin Bun Cheung

Statistical Design and Analysis of Clinical

Trials: Principles and Methods

Weichung Joe Shih and Joseph Aisner

Statistical Design and Analysis of

Stability Studies

Shein-Chung Chow

Statistical Evaluation of Diagnostic

Performance: Topics in ROC Analysis

Kelly H. Zou, Aiyi Liu, Andriy Bandos, Lucila Ohno-Machado, and Howard Rockette

Statistical Methods for Clinical Trials

Mark X. Norleans

Statistical Methods for Drug Safety

Robert D. Gibbons and Anup K. Amatya

Statistical Methods for Healthcare

Performance Monitoring

Alex Bottle and Paul Aylin

Statistical Methods for Immunogenicity

Assessment

Harry Yang, Jianchun Zhang, Binbing Yu, and Wei Zhao

Statistical Methods in Drug Combination

Wei Zhao and Harry Yang

Statistical Testing Strategies in the

Health Sciences

Albert Vexler, Alan D. Hutson, and Xiwei Chen

Statistics in Drug Research:

Methodologies and Recent **Developments**

Shein-Chung Chow and Jun Shao

Statistics in the Pharmaceutical Industry, Third Edition

Ralph Buncher and Jia-Yeong Tsay Survival Analysis in Medicine and

Genetics

Jialiang Li and Shuangge Ma

Theory of Drug Development

Eric B. Holmgren

Translational Medicine: Strategies and Statistical Methods Dennis Cosmatos and Shein-Chung Chow

List of Illustrations

Figure 6.1	Comparison of percentage of AVSD operations by age at operation (in months) between Bristol (UBHT) and elsewhere in England 1991/1992–1994/1995	97
Figure 9.1	An example of a run chart showing a run of eight data points below the median.	158
Figure 9.2	An example of a Shewhart chart of the data from the run chart of Figure 9.1, with upper and lower control limits with 3 SD on either side of the mean	159
Figure 9.3	An example of a funnel plot: inner lines represent 95% and outer lines 99.8% control limits.	160
Figure 11.1	Traffic light display of fictitious data on multiple indicators by unit.	190
Figure 11.2	Spider plot of an imaginary unit's fictitious data	192
Figure 11.3	Benchmarked performance for NHS West Essex CCG's commissioned elective knee surgery.	200
Figure 11.4	Example scatter plot from Public Health England's commissioning tool "Fingertips" showing CCG-level deprivation and adult inactivity.	201
Figure 11.5	Screenshot from NHS Choices.	203
Figure 11.6	Illustrative Hospital Compare results for three Seattle hospitals for readmissions and deaths in patients with COPD.	205
Figure 11.7	COPD readmission rates for three Seattle hospitals displayed as bar charts by Hospital Compare	205
Figure 12.1	Time segments pre- and post-intervention in an interrupted time series design.	211

List of Tables

Table 3.1	Main Methodological Issues When Considering the Unit of Analysis
Table 4.1	Structure, Process and Outcome Indicators Compared40
Table 4.2	Ways of Combining Quality and Cost Measures in a 2014 National Quality Forum White Paper56
Table 4.3	Attributes of Ideal Quality Indicators60
Table 5.1	Comparison of Key Features of Clinical and Administrative Databases
Table 6.1	Issues Associated with Common Patient Factors in Risk Models
Table 7.1	Summary of the Main Types of Standardised Mortality Ratio Derived from Logistic Regression or Standardisation with the National Average as the Benchmark Unless Specified Otherwise
Table 8.1	Main Steps in Composite Indicator Construction
Table 8.2	Common Options for Weighting and Combining Component Indicators in a Composite
Table 8.3	Main Pros and Cons of Healthcare Composite Measures148
Table 9.1	Common Ways to Compare Units155
Table 9.2	Common Definitions of Outlying Performance162
Table 10.1	Main Challenges for Maintaining an International Database for Benchmarking Outcomes
Table 11.1	Fictitious Data for Average Appointment Waiting Times by Unit with Categories and Star Rating
Table 11.2	Selected Public-Facing Websites for Obtaining Comparative Healthcare Unit Performance
Table 13.1	Trade-Offs in Healthcare Performance Monitoring226

Preface

Measurement is the first step that leads to control and eventually to improvement. If you can't measure something, you can't understand it. If you can't understand it, you can't control it. If you can't control it, you can't improve it.

H. James Harrington

Healthcare is important to everyone. A high standard of healthcare is even more important, yet large variations in quality have been well documented both between and within many countries. As populations grow older and medical care becomes more complex, expenditures continue to rise. It is therefore more crucial than ever to know how well the healthcare system and all its components are performing. This requires data, which inevitably differ in form and quality, and it requires statistical methods. Whether those methods are simple or complicated, their output has to be made understandable to whoever needs it, be it the patient choosing a doctor, the healthcare professional improving their own performance, the manager overseeing their unit, or the regulator assessing the whole system. This book covers measuring quality, types of data, risk adjustment, defining good and bad performance, statistical monitoring, presenting the results to different audiences, and evaluating the monitoring system itself. It thereby brings all the issues and perspectives together in a largely non-technical format for clinicians, managers and methodologists.

Both authors moved from environmental epidemiology to health services research in 2002, following our involvement with the public inquiries into two big UK scandals: (1) paediatric cardiac surgery at the Bristol Royal Infirmary and (2) general practice by Harold Shipman, the country's most prolific serial killer and family doctor. Applying what we had learned from our work to those public inquiries, Alex Bottle devised the details of our national hospital monitoring system that helped uncover a third scandal: the high death rate at Mid Staffordshire NHS Hospital Trust. Our unit's research focuses on developing indicators of quality and safety and care and understanding performance variations in primary care and between surgeons and hospitals in a range of specialties. We are also involved in quality improvement projects and work with psychologists to understand how clinical staff and managers use (or ignore) performance information. Alex conceived this book as a way to bring together all the elements of performance monitoring, with examples from around the world. We were also

keen for the algebra content to be as close to zero as possible, which it never is in statistics guides, not because writing formulae is fiddly, but because many statistical issues need to be understood by everyone interested in performance.

Alex Bottle
Paul Aylin
Imperial College London
United Kingdom

Authors

Alex Bottle is a senior lecturer in medical statistics in the School of Public Health at Imperial College London and methodological lead at the Dr. Foster Unit there. His background is in statistics and epidemiology, and he researches the use of large databases to measure and monitor the quality and safety of healthcare, with particular interests in risk adjustment, statistical process control and modelling multiple health service contacts in patients with chronic diseases. His fruitful collaborations with a wide range of clinicians, from anaesthetists to urologists, as well as with quality improvement scientists and the media, led him to conceive and write this book to bring all these worlds together.

Paul Aylin is a professor of epidemiology and public health at the School of Public Health at Imperial College London and leads the Dr. Foster Unit. After his medical training, he specialised in public health medicine and then spent three years at the Office for National Statistics in London before joining Imperial College in 1997. He became a Fellow of the Faculty of Public Health Medicine in 2001. He is a non-executive director at West London Mental Health NHS Trust. His research explores variations in indicators of quality and safety using routinely collected administrative data, including out-of-hours hospital mortality, the August (or July) effect, cancer care and indicators for late diagnosis. He has been an expert witness for both the Bristol Royal Infirmary and the Shipman public inquiries in the United Kingdom.

Contents

			115	
Pre	face			xix
Aut	thors			xxi
1.	Intro	duction	1	1
	1.1	The N	eed for Performance Monitoring	1
	1.2	Measu	ring and Monitoring Quality	2
	1.3	The N	ring and Monitoring Qualityeed for This Book	2
	1.4	Who Is	s This Book For and How Should It Be Used?	3
	Comi	non Ab	breviations Used in the Book	4
	Ackn	owledg	ment	6
2.	Origi	ins and	Examples of Monitoring Systems	7
	Aims	of This	Chapter	7
	2.1		ls	
	2.2	Health	ncare Scandals	8
		2.2.1	Responses to the Scandals	12
	2.3	Examp	oles of Monitoring Schemes	
	2.4	-	of Monitoring	
		2.4.1	Accountability	
		2.4.2	Regulation and Accreditation	
		2.4.3	Patient Choice	19
		2.4.4	Openness and Transparency	21
		2.4.5	Quality Improvement	
		2.4.6	Prevent Harm and Unsafe Care	
		2.4.7	Professionalism	
		2.4.8	Informed Consent	23
3.	Choo	sing th	e Unit of Analysis and Reporting	25
	Aims	of This	Chapter	25
	3.1	Issues	Principally Concerning the Analysis	26
		3.1.1	Clustering (*)	
		3.1.2	Episode Treatment Groups	
	3.2	Issues	More Relevant to Reporting: Attributing Performance	
			ven Unit in a System	34

4.	What	t to Measure: Choosing and Defining Indicators	37
	Aims	of This Chapter	37
	4.1	How Can We Define Quality?	38
	4.2	Common Indicator Taxonomies	38
	4.3	Particular Challenges of Measuring Patient Safety	42
	4.4	Particular Challenges of Multimorbidity	
	4.5	Measuring the Health of the Population and Quality	
		of the Whole Healthcare System	47
		4.5.1 The WHO Annual World Health Statistics Report	50
	4.6	Efficiency and Value	
		4.6.1 Data Envelopment Analysis and Stochastic Frontier	
		Analysis (*)	57
	4.7	Features of an Ideal Indicator	
	4.8	Steps in Construction and Common Issues in Definition	
	4.9	Validation of Indicators	
	4.10	Some Strategies for Choosing among Candidates	
	4.11	Time to Go: When to Withdraw Indicators	
	4.12	Conclusion.	
	1.14	Concidior	00
5.	Sour	ces of Data	67
		of This Chapter	
	5.1	How to Assess Data Quality	
	5.2	Administrative Data	
		5.2.1 Coding Systems for Administrative Data	
		5.2.2 Use of Administrative Databases to Flag Patient	
		5.2.2 Use of Administrative Databases to Flag Patient Safety Events	
	5.3	Safety Events	74
	5.3 5.4	Clinical Registry Data	74
	5.3 5.4	Safety Events	74 75
	5.4	Safety Events	74 75 77
	5.45.5	Safety Events	74 75 77 84
	5.4 5.5 5.6	Safety Events	74 75 77 84 87
	5.4 5.5 5.6 5.7	Safety Events	74 75 77 84 87
	5.4 5.5 5.6 5.7 5.8	Safety Events	74 75 77 84 87 89
	5.4 5.5 5.6 5.7	Safety Events	74 75 77 84 87 89
6.	5.4 5.5 5.6 5.7 5.8 5.9	Safety Events	74 75 84 87 89 90
6.	5.4 5.5 5.6 5.7 5.8 5.9 Risk-	Safety Events	74 75 77 84 87 90 91
6.	5.4 5.5 5.6 5.7 5.8 5.9 Risk-	Safety Events	74 75 77 84 87 90 91 93
6.	5.4 5.5 5.6 5.7 5.8 5.9 Risk-	Safety Events	74 75 77 84 87 90 91
6.	5.4 5.5 5.6 5.7 5.8 5.9 Risk- Aims 6.1 6.2	Safety Events	74 75 84 89 90 91
6.	5.4 5.5 5.6 5.7 5.8 5.9 Risk- Aims 6.1 6.2 6.3	Safety Events	74 75 84 87 90 91 93 93 94 95
6.	5.4 5.5 5.6 5.7 5.8 5.9 Risk- Aims 6.1 6.2 6.3 6.4	Safety Events	74 75 84 87 91 93 93 94 95 96
6.	5.4 5.5 5.6 5.7 5.8 5.9 Risk- Aims 6.1 6.2 6.3 6.4	Safety Events	747577848990919393949596
6.	5.4 5.5 5.6 5.7 5.8 5.9 Risk- Aims 6.1 6.2 6.3 6.4	Safety Events	74 75 84 87 91 91 93 94 95 96 96
6.	5.4 5.5 5.6 5.7 5.8 5.9 Risk- Aims 6.1 6.2 6.3 6.4	Safety Events	74 75 84 87 90 91 93 94 95 96 96 96

	6.5	Selecti	ng an Initial Set of Candidate Variables	101
	6.6	Dealin	ng with Missing and Extreme Values	102
	6.7		g of the Risk Factor Measurement	
	6.8		ng the Model	
		6.8.1	Choosing the Final Set of Variables from the	
		0.0.1	Initial Set of Candidates	108
		6.8.2	Decide How Each Variable Should Be Entered into	100
		0.0.2	the Model	111
		6.8.3	Decide on the Statistical Method for Modelling (*)	
		6.8.4		
		0.0.4	Assess the Fit of the Model (*)	
			6.8.4.1 Adjusted R ²	115
		l,	6.8.4.2 Area under the Receiver Operating	
			Characteristic Curve: c Statistic	115
			6.8.4.3 The Hosmer–Lemeshow Statistic for	
			Calibration	116
		6.8.5	Which Is More Important, Discrimination or	
			Calibration?	117
		6.8.6	What Can Be Done If the Model Fit or Performance	
			Is Unacceptable?	117
		6.8.7	Convert Regression Coefficients into a Risk Score	
			If Desired	118
7	Oute	ut the (Observed and Model-Predicted Outcomes (*)	101
1.	-			
	7.1		chapterversus Differences	
	7.2		ng SMRs from Standardisation and Logistic Regression.	
	7.3		Fixed Effects Approaches to Generate an SMR	
ŀ	7.4		m Effects–Based SMRs (*)	
	7.5		nal versus Multilevel Models (*)	
	7.6		Is the "Best" Modelling Approach Overall? (*)	130
	7.7		er Reading on Producing Risk-Adjusted	
		Outcor	mes by Unit	134
8.	Com	osite N	Measures	135
٠.			Chapter	
	8.1		Examples	
	8.2		n the Construction	
	0.2	8.2.1	Specify the Scope and Purpose	
		8.2.2	Choose the Unit	
		8.2.3	Select the Data and Deal with Missing Values	
		8.2.4	Choose the Indicators and Run Descriptive Analyses	
		8.2.5	Normalise the Metrics	140
		8.2.6	Assign Weights and Aggregate the Component	(grane)
			Indicators	
		8.2.7	Run Sensitivity Analyses	
		8.2.8	Present the Results	145

	8.3	Some Real Examples
		8.3.1 AHRQ's Patient Safety Indicator Composite
		8.3.2 Leapfrog Group Patient Safety Composite
	8.4	Pros and Cons of Composites
	8.5	Alternatives to the Use of Composites149
9.	Setti	ng Performance Thresholds and Defining Outliers151
	Aims	of This Chapter151
	9.1	Defining Acceptable Performance
		9.1.1 Targets
		9.1.2 Historical Benchmarks
		9.1.3 Referring to Inter-Unit Variation
	9.2	Bayesian Methods for Comparing Providers155
	9.3	Statistical Process Control and Funnel Plots
	9.4	Multiple Testing (*)
		9.4.1 Multivariate Statistical Process Control Methods (*) 165
		9.4.2 Further Reading on SPC
	9.5	Ways of Assessing Variation between Units
	9.6	How Much Variation Is "Acceptable"?167
	9.7	Impact on Outlier Status of Using Fixed versus Random
		Effects to Derive SMRs
	9.8	How Reliably Can We Detect Poor Performance?172
	9.9	Some Resources for Quality Improvement Methods 174
	III	
10.		ing Comparisons across National Borders177
		of This Chapter
		Examples of Multinational Patient-Level Databases
	10.2	Challenges
		10.2.1 Worked Example of Combining Administrative
		Databases from Multiple Countries: Stroke Mortality181
		10.2.2 Clustering within Countries
	10.2	10.2.3 Countries with Unusual Data or Apparent Performance184
	10.3	Interpreting Apparent Differences in Performance between Countries
	10.4	Conclusion
	10.4	Conclusion
11	Droco	enting the Results to Stakeholders
		of This Chapter
	11.1	The Main Ways of Presenting Comparative Performance Data 189
-		Effect on Behaviour of the Choice of Format When
	11.2	Providing Performance Data
	11.3	The Importance of the Method of Presentation
	11.0	11.3.1 Presenting Performance Data to
		Managers and Clinicians
. » L. \	1.1.12.1	11.3.2 Presenting Results to the Public
	7 i Ti	11.52 Tresenting Results to the Fublic annual Tresenting 197